Rare disease drugmaker Zevra Therapeutics Q1 revenue jumps 78%

Zevra Therapeutics

06/05/2026 21:58

Overview

U.S. rare disease drugmaker's Q1 revenue rose 78% yr/yr, beating analyst expectations

Company reported net income, reversing a loss in the prior-year quarter

Completed $50 mln SDX portfolio sale and repaid term loan, strengthening balance sheet

Outlook

Company expects available financial resources to be sufficient for strategic priorities without new capital

Zevra expects follow-up FDA meeting on DiSCOVER trial in H2 2026 to discuss development pathways

EMA review of arimoclomol for NPC ongoing, with application advancing through standard process

Result Drivers

MIPLYFFA SALES - Continued performance of MIPLYFFA for Niemann-Pick disease type C was the main revenue driver, per CEO Neil F. McFarlane

SDX PORTFOLIO SALE - $50 mln divestiture of the SDX portfolio provided a one-time gain and strengthened the financial position

EXPANDED ACCESS PROGRAM - $10.2 mln in net reimbursements from the global Expanded Access Program contributed to Q1 revenue

Company press release: ID:nGNX3xysHS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$36.22 mln
$31.96 mln (9 Analysts)
Q1 Net Income
$37.89 mln
Q1 Income from Operations
$52.15 mln
Q1 Operating Expenses
$25.18 mln
Q1 Pretax Profit
$44.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $23.50, about 121.5% above its May 5 closing price of $10.61

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)